Last Updated: August 2, 2026

XARACOLL Drug Patent Profile

✉ Email this page to a colleague

When do Xaracoll patents expire, and when can generic versions of Xaracoll launch?

Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-three patent family members in twenty-four countries.

The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xaracoll

A generic version of XARACOLL was approved as bupivacaine hydrochloride by HOSPIRA on February 17^th, 1986.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for XARACOLL?
What are the global sales for XARACOLL?
What is Average Wholesale Price for XARACOLL?

Summary for XARACOLL

International Patents:	83
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for XARACOLL

XARACOLL is protected by two US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Innocoll Pharms	XARACOLL	bupivacaine hydrochloride	IMPLANT;IMPLANTATION	209511-001	Aug 28, 2020		DISCN	Yes	No	RE47826	⤷ Start Trial				⤷ Start Trial
Innocoll Pharms	XARACOLL	bupivacaine hydrochloride	IMPLANT;IMPLANTATION	209511-001	Aug 28, 2020		DISCN	Yes	No	11,746,141	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for XARACOLL

See the table below for patents covering XARACOLL around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2013208952		⤷ Start Trial
Canada	2860552		⤷ Start Trial
Cyprus	1119524		⤷ Start Trial
Cyprus	1121643		⤷ Start Trial
Cyprus	1124160		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.